Search Results
Your search for ASCO matches 21361 pages
Showing 20551 - 20600Blinatumomab Receives FDA Priority Review Designation in Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application for blinatumomab for the treatment of adults with Philadelphia chromosome–negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). As part of the acceptance, the ...
FDA Approves Bortezomib Injection for Previously Untreated Patients With Mantle Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma. This is the first treatment in the United States to be approved for use in previously untreated patients with mantle cell lymphoma. Bortezomib was...
FDA Approves Netupitant and Palonosetron Combination Capsule for Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) today approved a combination of netupitant and palonosetron (Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. The new drug, also known as NEPA, is a fixed-combination capsule comprised of two agents: oral palonosetron,...
Study Finds Potential Link Between BRCA1/2 Mutations and Salivary Gland Cancer
The risk of developing cancer in a salivary gland might be higher in people with BRCA1 or BRCA2 mutations, which are associated with breast and ovarian cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital...
Study Identifies Groups at Risk for Gastrointestinal Stromal Tumors
Researchers at the University of California, San Diego, School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach and small intestine. Of note was the discovery that patients of Asian...
One in Three People With Cancer Has Anxiety or Other Mental Health Challenges
Researchers in Germany report that nearly one-third of more than 2,100 patients with cancer interviewed at inpatient and outpatient care centers experienced a clinically meaningful level of mental or emotional distress that meets the strict diagnostic criteria for mental disorders including...
Fiber-Based Laxatives Linked to Decreased Risk of Colorectal Cancer
A large, prospective study involving more than 75,000 adults in western Washington has found that frequent use of fiber-based laxatives is associated with a decreased risk of colorectal cancer. The study also found that use of nonfiber laxatives is linked to significantly increased risk of...
FDA Grants Orphan Drug Designation to DNX-2401 for Malignant Glioma
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DNAtrix’s DNX-2401, a conditionally-replicative oncolytic adenovirus for malignant glioma. Glioma is the most common form of primary brain cancer, the treatment of which remains a significant unmet medical...
2014 Nobel Prize in Physiology or Medicine Awarded to John O’Keefe, FRS, May-Britt Moser, PhD, and Edvard I. Moser, PhD
The Nobel Assembly at Karolinska Institutet has awarded the 2014 Nobel Prize in Physiology or Medicine to John O’Keefe, FRS, and to May-Britt Moser, PhD, and Edvard I. Moser, PhD, for their discoveries of cells that constitute a positioning system in the brain. This “inner GPS”...
Study Finds Increase in Colonoscopy Rates Has Lead to Overuse
A retrospective study led by researchers at Brigham and Women's Hospital has found an overuse of colonoscopies for colorectal cancer screening and surveillance. The study demonstrated that endoscopists commonly recommended shorter follow-up intervals than established guidelines support, and these...
FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pegylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Halozyme Therapeutics is currently investigating PEGPH20 in a phase II study in combination with gemcitabine and...
Researchers Discover Genetic Variant That Can Predict Aggressive Prostate Cancer at Diagnosis
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker adjacent to the KLK3 gene that can predict which prostate cancer patients with a Gleason score of 7 will have a more aggressive form of cancer. The findings by He et al, published in Clinical Cancer...
FDA Grants Breakthrough Therapy Designation to AP26113 for ALK-Positive NSCLC
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Ariad Pharmaceutical’s investigational agent AP26113 for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) who are resistant to crizotinib...
ESMO 2014: Abiraterone Plus Prednisone Significantly Improves Overall Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A final analysis of the phase III COU-AA-302 trial showed that abiraterone acetate (Zytiga) plus prednisone significantly prolonged overall survival compared to an active control of placebo plus prednisone in men with chemotherapy-naive metastatic castration-resistant prostate cancer. The study,...
ESMO 2014: Everolimus Improves Overall Survival in Patients With Advanced Pancreatic Neuroendocrine Tumors
In a phase III trial, treatment with everolimus (Afinitor) resulted in a median overall survival of over 3 and a half years in patients with well-differentiated and progressive pancreatic neuroendocrine tumors, representing what the study authors called a "clinically important" although not...
ESMO 2014: Nivolumab Shows Signs of Superior Response Rate Compared to Standard Chemotherapy in Advanced Melanoma
The monoclonal antibody nivolumab achieved superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab (Yervoy), according to preliminary data from a phase III trial presented at the ESMO 2014...
Robert S. Miller, MD, FACP, FASCO, Joins ASCO as Medical Director for Society's Institute for Quality
Robert S. Miller, MD, FACP, FASCO, Assistant Professor of Oncology and Oncology Medical Information Officer at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, has been named Medical Director of the Institute for Quality (iQ) of the American Society of Clinical Oncology (ASCO). ...
ESMO 2014: Adding Cediranib to Chemotherapy Improves Progression-Free Survival in Metastatic or Recurrent Cervical Cancer
For patients with recurrent or metastatic cervical cancer, adding the experimental drug cediranib to standard chemotherapy improved tumor shrinkage and resulted in a modest improvement in progression-free survival, researchers reported at the ESMO 2014 Congress in Madrid (Abstract LBA25_PR). In...
Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and...
ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer
In the final overall survival analysis of the phase III CLEOPATRA trial, patients with HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the ESMO 2014...
Screening for and Treating Early-Stage Lung Cancer Is Less Costly Than Treating Late-Stage Disease
A new study found that the average cost to screen high-risk individuals for lung cancer with low-dose computed tomography (CT) plus the average cost of curative-intent treatment is lower than the average cost to treat advanced-stage lung cancer, which quite rarely results in a cure. The findings by ...
FDA Grants Orphan Drug Designation to Bivalent Vaccine for Neuroblastoma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MabVax Therapeutics’ vaccine for the treatment of relapsed or recurrent high-risk neuroblastoma in remission or with limited residual disease after best available treatment. The bivalent vaccine is intended to...
Preclinical Study Identifies Potential Drug Combination for Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Combining the molecular targeted drug ibrutinib (Imbruvica) with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma and chronic lymphocytic leukemia (CLL), according to preclinical data presented at the American Association for Cancer Research...
Second-Line Ramucirumab Plus Paclitaxel Improves Overall Survival in Patients With Advanced Gastric Cancer
The addition of the monoclonal antibody VEGFR-2 antagonist ramucirumab (Cyramza) to paclitaxel led to a statistically significant improvement in median overall survival in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma in a phase III trial, reported Wilke et al in ...
Lymphatic Mapping Agent Receives Orphan Drug Designation for Head and Neck Cancers
Navidea Biopharmaceuticals, Inc, recently announced that technetium 99m tilmanocept (Lymphoseek Injection) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for use in sentinel lymph node detection in patients with cancer of the head and neck. The designation...
ASTRO: Analysis Finds Select Group of Stage IV Lung Cancer Patient Population Achieves Long-Term Survival After Aggressive Treatment
A large, international analysis of patients with stage IV non–small cell lung cancer (NSCLC) indicates that a patient’s overall survival rate can be related to factors including the timing of when metastases develop and lymph node involvement, and that aggressive treatment for low-risk...
ASTRO: Good Primary Tumor Control, Positive 5-Year Survival Rates for Lung Cancer Patients Who Receive Stereotactic Body Radiation Therapy
Patients with inoperable, early-stage lung cancer who receive stereotactic body radiation therapy have a 5-year survival rate of 40%, according to long-term results presented at the American Society for Radiation Oncology’s (ASTRO) 56th Annual Meeting (Abstract 56). Such a positive survival...
ASTRO: Long-Term Androgen-Deprivation Therapy Plus High-Dose Radiation Therapy Improves Biochemical Control and Survival Rates in Prostate Cancer
Prostate cancer patients who receive high-dose radiation therapy followed by a longer period of androgen-deprivation therapy have higher 5-year biochemical disease–free survival and overall survival rates compared to patients who receive high-dose radiation therapy and a shorter duration of...
ASTRO: Radiation Therapy Does Not Increase Risk of Lymphedema in Node-Negative Breast Cancer
A secondary analysis of the National Surgical Adjuvant Breast and Bowel Project B-32 trial indicates that radiation therapy does not increase the incidence of lymphedema in patients with node-negative breast cancer, according to research presented at the American Society for Radiation...
ASTRO: Pretreatment Serum Levels of VEGF-A and TGF-β1 Predictive of Outcomes in Esophageal Cancer
Serum levels of VEGF-A and TGF-β1 may be helpful in tailoring neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma, according to research presented at the American Society for Radiation Oncology’s (ASTRO) 56th Annual Meeting (Abstract 10). Results of...
ASTRO: Radiation Therapy Alone vs Chemoradiotherapy for Reducing Dysphagia in Advanced Esophageal Cancer
Radiation therapy alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as radiation therapy combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented at the American Society for Radiation...
ASTRO: Shorter Course of Androgen-Deprivation Therapy Yields Improved Quality of Life for High-Risk Prostate Cancer Patients
Patients with high-risk prostate cancer who received radiation therapy and an 18-month course of androgen-deprivation therapy recovered a normal testosterone level in a shorter amount of time compared to those who received a 36-month course of androgen-deprivation therapy. The shorter course of...
ASTRO: Radiation Therapy Improves Survival in Patients With Early-Stage Hodgkin Lymphoma
Patients with stage I and II Hodgkin lymphoma who received consolidated radiation experienced improved 10-year survival rates, according to research presented at the American Society for Radiation Oncology (ASTRO) 56th Annual Meeting (Abstract CT-08). The 10-year survival rate for patients who...
Genomic Analysis Reveals That a High-Risk Leukemia Subtype Becomes More Common With Age
More than one-quarter of young adults with the most common form of acute lymphoblastic leukemia have a high-risk subtype with a poor prognosis and may benefit from drugs widely used to treat other types of leukemia that are more common in adults, according to multi-institutional research led by St. ...
FDA Approves New Indication for Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
The U.S. Food and Drug Administration (FDA) has approved a new indication for the use of enzalutamide (Xtandi) capsules to treat patients with metastatic castration-resistant prostate cancer. The new indication is for men with metastatic castration-resistant prostate cancer who have not received...
Radiation Therapy With Concurrent Chemotherapy After Surgery Is an Effective Treatment for High-Risk Endometrial Cancer
Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for high-risk endometrial cancer, according to a study reported by Cho et al in the International Journal of Radiation Oncology • Biology • Physics Endometrial...
ASCO and Cancer Care Ontario Release Clinical Practice Guideline for Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer
The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline is reported by Basch et al in the Journal of...
Phase II Trial Shows Overall Survival Benefit With VT-122 Plus Sorafenib in Advanced Hepatocellular Carcinoma
The investigational agent VT-122 appeared to benefit survival when combined with sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma, according to data presented at the 8th Annual International Liver Cancer Association Conference in Kyoto, Japan. Researchers reported an 11-month...
Breast-Conserving Therapy Shows Survival Benefit Over Mastectomy in Patients With Early-Stage Hormone Receptor–Positive Disease
When factoring in what is now known about breast cancer biology and heterogeneity, breast-conserving therapy may offer a greater survival benefit over mastectomy to women with early-stage, hormone receptor–positive disease, according to research from The University of Texas MD Anderson Cancer ...
Once-Weekly Breast Irradiation Following Lumpectomy Results in Better Compliance, Lower Costs, and Comparable Cosmetic Outcomes vs Daily Treatment
An experimental regimen of once-weekly breast irradiation following lumpectomy provides more convenience to patients at a lower cost, results in better completion rates of prescribed radiation treatment, and produces cosmetic outcomes comparable to the current standard of daily radiation. These...
Disparities Persist in Early-Stage Breast Cancer Treatment
Despite its acceptance as standard of care for early-stage breast cancer almost 25 years ago, barriers still exist that preclude patients from receiving breast-conserving therapy, with some still opting for a mastectomy, according to research from The University of Texas MD Anderson Cancer Center....
Novel Immunotherapy Vaccine Decreases Recurrence in HER2-Positive Breast Cancer Patients
A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. These findings were presented at the 2014 Breast...
FDA Approves Pembrolizumab for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to the anti–PD-1 antibody pembrolizumab (Keytruda) for the treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs. Pembrolizumab is intended for use following...
ASCO Issues New Guideline on Chemotherapy and Targeted Therapy in Advanced HER2-Negative or Unknown HER2 Status Breast Cancer
The American Society of Clinical Oncology has released a new clinical practice guideline on chemotherapy and targeted therapy for women with advanced HER2-negative or unknown HER2 status breast cancer. The guideline is published in the Journal of Clinical Oncology. In formulating the consensus...
Survey Reveals Factors Influencing Women’s Consideration of Contralateral Prophylactic Mastectomy
A survey of 150 women newly diagnosed with breast cancer provides new insight into factors that influence women’s decisions to undergo contralateral prophylactic mastectomy. This is one of the first studies to look at women’s breast surgery preferences prospectively, before they undergo ...
Breast Cancer Surgery and Reconstruction Complications Are Rare, but Risk of Some Complications Higher With Bilateral vs Unilateral Mastectomy
A new analysis of 30-day post-surgery complications among more than 18,000 women with breast cancer undergoing bilateral and unilateral mastectomy with breast reconstruction found that complications were generally rare for either type of surgery, with an overall rate of complications of 5.3%....
Family Physician–Signed Reminder Letters Improve Return Rates for Women Overdue for Screening Mammography
A large study conducted through the BC Cancer Agency in British Columbia, Canada, reports that adding family physician–signed reminder letters to the standard schedule of postcard reminders substantially improves return rates for screening among women who are overdue for such screening. In a...
FDA Grants Priority Review to Lanreotide Injection for Gastroenteropancreatic Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review to Ipsen’s supplemental New Drug Application (sNDA) for the somatostatin analog lanreotide (Somatuline Depot) 120 mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors. The FDA...
Response to Neoadjuvant Chemotherapy and Tumor Subtype Are Strong Predictors of Locoregional Breast Cancer Recurrence
An analysis of data from 12 large clinical trials found that the cancer’s pathologic response to neoadjuvant chemotherapy and tumor subtype are strong predictors of locoregional breast cancer recurrence. According to the researchers, the study showed that these two predictors may be more...
Angelina Jolie’s Story May Have Helped Double BRCA Testing Rates at a Canadian Cancer Center
A retrospective review of records at an academic cancer center in Ontario, Canada, found that referrals for genetic counseling and the rates of genetic testing performed almost doubled over the 6-month period after Angelina Jolie announced she underwent a preventive double mastectomy because she...
